Veracyte Inc (VCYT)

Debt-to-equity ratio

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Long-term debt US$ in thousands — — — — — — — — — — — — — — — — — — — —
Total stockholders’ equity US$ in thousands 1,221,060 1,194,940 1,175,970 1,176,040 1,132,520 1,118,650 1,044,100 1,054,060 1,082,720 1,081,260 1,075,200 1,048,180 1,064,150 1,085,190 1,096,510 1,107,080 971,177 974,231 421,232 422,725
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

June 30, 2025 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1,221,060K
= 0.00

The data indicates that Veracyte Inc consistently maintained a debt-to-equity ratio of zero across all reporting periods from September 30, 2020, through June 30, 2025. This steadfastly zero ratio suggests that the company has not utilized debt financing during this period and has likely financed its operations entirely through equity or internal cash flows. The absence of leverage implies a conservative capital structure, potentially minimizing financial risk associated with debt obligations. Overall, the company's financial strategy appears to favor equity financing, with no reliance on external debt sources as reflected in this ratio over the observed timeline.